Cited by 87Regulation of Appetite and ObesityGastrointestinal motility and disordersAdipokines, Inflammation, and Metabolic Diseases

Augmented capacity for peripheral serotonin release in human obesity

Young, Richard L., Lumsden, Amanda L., Martin, Alyce M., Schober, Gudrun, Pezos, Nektaria, Thazhath, Sony S., Isaacs, Nicole J., Cvijanovic, Nada +13 more·2018·International Journal of Obesity

Abstract

Background/objectives Evidence from animal studies highlights an important role for serotonin (5-HT), derived from gut enterochromaffin (EC) cells, in regulating hepatic glucose production, lipolysis and thermogenesis, and promoting obesity and dysglycemia. Evidence in humans is limited, although elevated plasma 5-HT concentrations are linked to obesity.Subjects/methods We assessed (i) plasma 5-HT concentrations before and during intraduodenal glucose infusion (4 kcal/min for 30 min) in non-diabetic obese (BMI 44 ± 4 kg/m 2, N = 14) and control (BMI 24 ± 1 kg/m 2, N = 10) subjects, (ii) functional activation of duodenal EC cells (immunodetection of phospho-extracellular related-kinase, pERK) in response to glucose, and in separate subjects, (iii) expression of tryptophan hydroxylase-1 (TPH1) in duodenum and colon (N = 39), and (iv) 5-HT content in primary EC cells from these regions (N = 85).Results Plasma 5-HT was twofold higher in obese than control responders prior to (P = 0.025), and during (iAUC, P = 0.009), intraduodenal glucose infusion, and related positively to BMI (R 2 = 0.334, P = 0.003) and HbA1c (R 2 = 0.508, P = 0.009). The density of EC cells in the duodenum was twofold higher at baseline in obese subjects than controls (P = 0.023), with twofold more EC cells activated by glucose infusion in the obese (EC cells co-expressing 5-HT and pERK, P = 0.001), while the 5-HT content of EC cells in duodenum and colon was similar; TPH1 expression was 1.4-fold higher in the duodenum of obese subjects (P = 0.044), and related positively to BMI (R 2 = 0.310, P = 0.031).Conclusions Human obesity is characterized by an increased capacity to produce and release 5-HT from the proximal small intestine, which is strongly linked to higher body mass, and glycemic control. Gut-derived 5-HT is likely to be an important driver of pathogenesis in human obesity and dysglycemia.

Integrity signals

Registry

Crossref · 10.1038/s41366-018-0047-8

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Gut-derived 5-HT can modulate glucose and energy homeostasis and is augmented in patients with type 2 diabetes and the obese.

    “Furthermore, gut-derived 5-HT can also modulate glucose and energy homeostasis (68-70), and is augmented in patients with type 2 diabetes (71) and the obese (9).”

The citation lists haven’t been fetched yet

References 41 · Cited by 87

Authors
Young, R. L., Lumsden, A. L., Martin, A. M., Schober, G., Pezos, N., Thazhath, S. S., Isaacs, N. J., Cvijanovic, N., Sun, E. W. L., Wu, T., Rayner, C. K., Nguyen, N. Q., Fontgalland, D. D., Rabbitt, P., Hollington, P., Sposato, L., Due, S. L., Wattchow, D. A., Liou, A. P., Jackson, V. M., & Keating, D. J.
Affiliations
  • South Australian Health and Medical Research Institute (AU)
  • Flinders University (AU)
  • The University of Adelaide (AU)
  • Flinders Medical Centre (AU)
  • Pfizer (United States) (US)
Corresponding author
Keating, Damien J.
Venue
International Journal of Obesity
Published
2018-03-01
Volume
42
Issue
11
Pages
1880-1889
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W2790248748
Cited by
87
References
41
Citations by year
2026: 9 · 2025: 7 · 2024: 9 · 2023: 9 · 2022: 13 · 2021: 15 · 2020: 13 · 2019: 9 · 2018: 3
FWCI
5.64
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
Royal Adelaide Hospital
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
serotonin, obesity, enterochromaffin cells, gut-brain axis, tryptophan hydroxylase 1, intraduodenal glucose infusion, plasma serotonin, extracellular signal-regulated kinase, dysglycemia, HbA1c, gastrointestinal hormones, body mass index, dyslipidemia
MeSH terms
Adult, Blood Glucose, Cells, Cultured, Colon, Enterochromaffin Cells, Female, Humans, Male, Middle Aged, Obesity, Serotonin, Signal Transduction, Endoscopy, Gastrointestinal, Peripheral Nervous System, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review